Jeffrey T. Jensen

Women aged ≤25 and >25 years have a similar experience with an E2V/DNV oral contraceptive, supporting this as an appropriate contraceptive option in younger and older women.

OBJECTIVE: To review the available clinical evidence on the use of combined hormonal contraceptive (CHC) agents (estrogen [E]-progestin combinations) for the treatment of endometriosis-related pain. DESIGN: A systematic review of the MEDLIN…

BACKGROUND: The avoidance of menstruation through continuous or extended (greater than 28 days) administration of combination hormonal contraceptives (CHCs) has gained legitimacy through its use in treating endometriosis, dysmenorrhea, and …

Дослідження проведене з метою оцінки клінічної ефективності естрадіолу валерату/дієногесту (Е2В/ДН Г ), який приймався в режимі доз естрогенів, що знижуються, і доз прогестагену, що підвищуються, в 28-денному режимі для лікування інтенсивни…

Abstract: Three estradiol (E 2 )-containing oral contraceptives, estradiol valerate/cyproterone acetate (E 2 V/CPA, Femilar ® ), estradiol valerate/dienogest (E 2 V/DNG, Qlaira ® /Natazia™), and estradiol/nomegestrol acetate (E 2 /NOMAC; Zo…

OBJECTIVES: To determine the effect of oestradiol valerate/dienogest (E2V/DNG) versus ethinylestradiol/norgestimate (EE/NGM) on hormone-withdrawal associated symptoms (HWAS) in otherwise healthy women who had experienced at least one of the…

OBJECTIVES: To quantify the change in work productivity and activities of daily living in North American women with heavy menstrual bleeding (HMB) treated with estradiol valerate/dienogest (E2V/DNG; Qlaira(®)/Natazia(®)) compared to placebo…

Objectives: This study evaluated the healthcare resource use, work productivity loss, costs, and treatment patterns associated with newly diagnosed idiopathic heavy menstrual bleeding (HMB) using a large employer database. Methods: Medical …

BACKGROUND: This double-blind trial investigated the efficacy and safety of estradiol valerate/dienogest (E(2)V/DNG) for the treatment of heavy menstrual bleeding without recognizable organic pathology. METHODS: Otherwise healthy women with…

OBJECTIVES: To evaluate the efficacy of oestradiol valerate/dienogest (E2V/DNG) for the treatment of heavy and/or prolonged menstrual bleeding without organic pathology based on the analysis of data from two identically designed double-blin…

OBJECTIVE: To estimate the efficacy of a fixed estrogen step-down and progestin step-up 28-day estradiol (E2) valerate and dienogest oral contraceptive regimen in women with heavy menstrual bleeding, prolonged menstrual bleeding, or heavy a…

Estradiol valerate and dienogest have been combined to create a novel four-phasic oral contraceptive pill effective for both pregnancy prevention and treatment of heavy menstrual bleeding. This formulation represents the only oral contracep…

IMPORTANCE OF THE FIELD: Since ethinyl estradiol is a potent activator of hepatic enzymes, the use of natural estradiol (E2) has been studied; but, until recently, bleeding control has hampered development of an E2 pill. AREAS COVERED IN TH…

Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS Paula H Bednarek, Jeffrey T JensenDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USAAbst…

Although officially approved as a contraceptive, the device is also finding a role in several benign gynecologic disorders. One expert examines the evidence for its use in menorrhagia, fibroids, endometriosis, adenomyosis, and endometrial h…